Pharmaceuticals

Herbalgy Unveils Touch Cool Campaign at MTR* advertising: An Immersive Installation Fusing Pain Relief with Sustainability and Innovative Design

Download high-resolution images:    https://cutt.ly/srswmUXq HONG KONG, April 17, 2025 /PRNewswire/ -- Herbalgy Pharmaceutical Ltd. is pleased to unveil its latest public engagement initiative at MTR* advertising, the leading outdoor media plat...

2025-04-17 10:00 3601

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

* IFINWIL®: now TGA registered in Australia * Children diagnosed with neuroblastoma are on average just 2 years old2 * The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic...

2025-04-17 08:01 2708

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and ...

2025-04-17 08:01 2951

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the lat...

2025-04-16 23:30 4194

The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months

SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results ofziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd....

2025-04-16 09:00 4584

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131 I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substan...

2025-04-16 06:45 3078

Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount to €350,000

Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has been granted a growing reputation as a prelude to the Nobel Prize since it has distinguished in a former edition two authors subsequently honoured with the Nobel Prize in Medic...

2025-04-15 15:00 3425

Wang Qunbin: Leveraging Innovation and Global Operational Strengths to Contribute "Fosun Power" to the Development of Hainan Free Trade Port

HONG KONG and SHANGHAI, April 15, 2025 /PRNewswire/ -- On April 14, the 2025 Hainan Free Trade Port Global Investment Promotion Conference was held inHaikou . Jointly hosted by the People's Government ofHainan Province and the Ministry of Commerce, the conference is one of the key events in the 20...

2025-04-15 12:05 4067

Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal

CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) for the treatment o...

2025-04-12 17:20 5078

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved

SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with mod...

2025-04-10 19:23 8438

Medtec Southeast Asia 2025 - The Southeast Asia's Premier Medical Device Design & Manufacturing Exhibition Debuts in Malaysia

KUALA LUMPUR, Malaysia, April 10, 2025 /PRNewswire/ -- Informa Markets announces the launch ofMedtec Southeast Asia 2025, the premier medical device design and manufacturing exhibition inSoutheast Asia, making its debut in Malaysia. The inaugural Medtec Southeast Asia 2025 exhibition will take p...

2025-04-10 16:58 6568

Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation

- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation systemexpected to cover the entire PCR workforce, from sample pre-processing to result analysis. - Designed for 24-hour, seven-days-a-week, unattended, CURECA™ reflects the company's mission to ...

2025-04-09 21:00 4980

Asia Health & Medlab Asia Rebrands to WHX and WHX Labs in Kuala Lumpur and Bangkok

KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- The global event organisation leader Informa Markets revealed a major rebranding of its healthcare exhibitions portfolio which resulted in the formation of WHX (World Health Expo). WHX rebrands its healthcare events acrossSoutheast Asia to WHX...

2025-04-09 19:49 5642

Alpro Pharmacy Now Offers Free AIA Vitality Health Check to Support Early Disease Detection

KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- Millions of Malaysians are at risk of serious health complications due to undiagnosed and unmanaged non-communicable diseases (NCDs), such as diabetes, hypertension, high cholesterol, and obesity. According to the National Health and Morbidity...

2025-04-09 10:00 3647

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

* This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development. * The partnership will advance the development of first-in-class precision therapeutics for multiple cancer ty...

2025-04-08 09:00 3241

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectivelydeliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and n...

2025-04-07 08:34 6258

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to becomeEmerald ...

2025-04-07 08:00 4017

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr.Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.   Dr. Schaffer has...

2025-04-07 07:09 4774

IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery

De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identific...

2025-04-03 07:45 5951

LBB Specialties Partners with Kerry Group to Launch Pharmaceutical Lactose to the Life Sciences Market

NORWALK, Conn., April 3, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution in North America, is pleased to announce a new partnership with Kerry Group, a world leading taste and nutrition partner for the food, beverage, and pharmaceutical mark...

2025-04-03 01:30 3339
1 ... 47484950515253 ... 184